Study: NCT04363983

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Blood collection (50 ml) will be performed for all patients at baseline, at 1 month post-operative for resected patients (+ at the end of neoadjuvant treatment / before surgery if patient receives neoadjuvant treatment), and at 2-3 months after the beginning of the treatments in patients with metastases (+ at each progression).~Following analysis should be performed with~* serum for protein assays and characterization analysis of cytokines, new tumor markers and micro-RNA ...;~* plasma for protein assays and characterization analysis of micro-RNA, VEC (the content of proteins, RNA, micro-RNA and DNA) and metabolomics;~* PBMC for flow cytometry analysis, isolation macrophages;~* whole blood for circulating tumor DNA (mutations by NGS, ddPCR,...; methylation) and circulating tumor cells.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Blood collection (50 ml) will be performed for all patients at baseline, at 1 month post-operative for resected patients (+ at the end of neoadjuvant treatment / before surgery if patient receives neoadjuvant treatment), and at 2-3 months after the beginning of the treatments in patients with metastases (+ at each progression).~Following analysis should be performed with~* serum for protein assays and characterization analysis of cytokines, new tumor markers and micro-RNA ...;~* plasma for protein assays and characterization analysis of micro-RNA, VEC (the content of proteins, RNA, micro-RNA and DNA) and metabolomics;~* PBMC for flow cytometry analysis, isolation macrophages;~* whole blood for circulating tumor DNA (mutations by NGS, ddPCR,...; methylation) and circulating tumor cells.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Blood collection (50 ml) will be performed for all patients at baseline, at 1 month post-operative for resected patients (+ at the end of neoadjuvant treatment / before surgery if patient receives neoadjuvant treatment), and at 2-3 months after the beginning of the treatments in patients with metastases (+ at each progression).~Following analysis should be performed with~* serum for protein assays and characterization analysis of cytokines, new tumor markers and micro-RNA ...;~* plasma for protein assays and characterization analysis of micro-RNA, VEC (the content of proteins, RNA, micro-RNA and DNA) and metabolomics;~* PBMC for flow cytometry analysis, isolation macrophages;~* whole blood for circulating tumor DNA (mutations by NGS, ddPCR,...; methylation) and circulating tumor cells.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Blood collection (50 ml) will be performed for all patients at baseline, at 1 month post-operative for resected patients (+ at the end of neoadjuvant treatment / before surgery if patient receives neoadjuvant treatment), and at 2-3 months after the beginning of the treatments in patients with metastases (+ at each progression).~Following analysis should be performed with~* serum for protein assays and characterization analysis of cytokines, new tumor markers and micro-RNA ...;~* plasma for protein assays and characterization analysis of micro-RNA, VEC (the content of proteins, RNA, micro-RNA and DNA) and metabolomics;~* PBMC for flow cytometry analysis, isolation macrophages;~* whole blood for circulating tumor DNA (mutations by NGS, ddPCR,...; methylation) and circulating tumor cells.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Blood collection (50 ml) will be performed for all patients at baseline, at 1 month post-operative for resected patients (+ at the end of neoadjuvant treatment / before surgery if patient receives neoadjuvant treatment), and at 2-3 months after the beginning of the treatments in patients with metastases (+ at each progression).~Following analysis should be performed with~* serum for protein assays and characterization analysis of cytokines, new tumor markers and micro-RNA ...;~* plasma for protein assays and characterization analysis of micro-RNA, VEC (the content of proteins, RNA, micro-RNA and DNA) and metabolomics;~* PBMC for flow cytometry analysis, isolation macrophages;~* whole blood for circulating tumor DNA (mutations by NGS, ddPCR,...; methylation) and circulating tumor cells.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Blood collection (50 ml) will be performed for all patients at baseline, at 1 month post-operative for resected patients (+ at the end of neoadjuvant treatment / before surgery if patient receives neoadjuvant treatment), and at 2-3 months after the beginning of the treatments in patients with metastases (+ at each progression).~Following analysis should be performed with~* serum for protein assays and characterization analysis of cytokines, new tumor markers and micro-RNA ...;~* plasma for protein assays and characterization analysis of micro-RNA, VEC (the content of proteins, RNA, micro-RNA and DNA) and metabolomics;~* PBMC for flow cytometry analysis, isolation macrophages;~* whole blood for circulating tumor DNA (mutations by NGS, ddPCR,...; methylation) and circulating tumor cells.